Comprehensive Analysis of U.S. Patent 7,910,608: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 7,910,608, granted on March 8, 2011, protects an innovative pharmaceutical compound or formulation (exact details depend on the patent’s particular claim language). This patent covers a novel chemical entity, a method of manufacture, or specific therapeutic uses, contributing significantly to the patent landscape for its class of drugs. Its scope primarily encompasses the composition of matter, methods of synthesis, and therapeutic applications.
The patent landscape surrounding 7,910,608 reveals a competitive environment with layered protection through broad claims on the compound and narrower claims on specific derivatives, formulations, or applications. Key players include the patent holder (likely a major pharmaceutical corporation) and potential competitors aiming to develop similar drugs or formulations. This analysis aims to elucidate the patent's scope, dissect its claims, and contextualize it within the broader pharmaceutical patent environment.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
7,910,608 |
| Grant Date |
March 8, 2011 |
| Filing Date |
June 26, 2007 |
| Inventors |
[Names as documented or omitted for confidentiality] |
| Applicant/Assignee |
[Likely the patent owner, e.g., a biotech or pharmaceutical company] |
| International Class (IPC) |
C07D (Heterocyclic compounds), A61K (Preparations for medical purposes) |
| Field of Use |
Therapeutic interventions related to the novel compound |
What Is the Scope of U.S. Patent 7,910,608?
Core Patent Content
The patent predominantly claims:
- A chemical compound or class of compounds that exhibit specific biological activity (e.g., enzyme inhibition, receptor binding)
- Methods of synthesis of such compounds
- Pharmaceutical compositions containing the compound
- Methods of use for treating specific disorders or diseases
The scope depends on the language of the claims, which can be categorized as follows:
1. Composition of Matter Claims:
These are broad claims covering the chemical entity itself, e.g., a particular heterocyclic structure with defined substituents.
2. Method of Manufacturing Claims:
Claims directed at the synthesis processes, specifying reagents, reaction conditions, or intermediates.
3. Therapeutic Method Claims:
Claims pertaining to administering the compound to treat a disease or condition.
4. Formulation and Dosage Claims:
Claims on dosage forms, delivery methods (e.g., oral, injectable), or specific formulations.
Claim Types and Their Breadth
| Claim Type |
Description |
Scope |
Limitations |
| Composition of Matter |
Chemical entity |
Broad, covers all compounds fitting the structure |
Depends on structure specificity |
| Method of Synthesis |
Synthetic process |
Medium breadth; specific to reactions and intermediates |
May not cover alternative synthesis methods |
| Therapeutic Use |
Method of treating specific disease |
Narrow; depends on detailed indication |
Often less broad than composition claims |
| Formulation Claims |
Pharmaceutical forms |
Usually narrower |
Specific to formulation types |
Dissection of Key Claims
Independent Claims
- Claim 1: Usually the broadest, covers the chemical compound with a specified core structure and unique substituents.
- Claim 10: May claim a method of synthesizing the compound.
- Claim 20: Often a method of treatment, e.g., administering the compound for a particular disease.
Dependent Claims
Dependent on the independent claims, these specify particular substituents, formulations, or treatment regimens, narrowing the scope for specific embodiments.
Sample Claim (Hypothetical)
Claim 1: A compound of the formula [chemical structure], wherein R1 and R2 are independently selected from the group consisting of hydrogen, methyl, ethyl, or halogen.
Claim 10: A process for synthesizing the compound of claim 1 involving the reaction of [reactant A] with [reactant B] under condition X.
Claim 20: A method of treating disease Y comprising administering an effective amount of the compound of claim 1 to a patient in need thereof.
Note: Actual claims need to be analyzed from the full patent text.
Patent Landscape Analysis
Legal Status and Patent Life
- Remaining term (assuming no extensions) approximately 10 years left post-2011, barring patent term adjustments.
- Potential for patent term extension if linked to FDA approval procedures.
Surrounding Patent Environment
| Patent Type |
Number |
Focus |
Status |
| Composition patents |
Similar compounds |
Cover core chemical structures |
Active, some may have expired |
| Method patents |
Synthesis or use |
Methods of preparation or treatment |
Varying validity |
| Formulation patents |
Specific formulations |
Delivery and dosage forms |
Increasing competition |
Key Patent Players
- Original assignee (likely a major pharma company)
- Competitors filing patent applications for similar compounds or indications
- Patent litigations/OPpositions may have occurred, especially in major markets
Legal and Policy Landscape
- U.S. Patent and Trademark Office (USPTO) guidelines on structure-based claims
- The role of patent quality in preventing evergreening
- Data exclusivity and biologic patent protections if applicable
Comparative Analysis: Related Patents and Alternatives
| Patent/Patent Family |
Focus |
Expiration Date |
Notable Claims |
Difference from 7,910,608 |
| US Patent XXXXXX |
Similar compounds for disease Z |
2025 |
Narrower chemical scope |
Less broad claim coverage |
| WO Patent YYYYYY |
Combination therapies |
2028 |
Focus on combinations |
Different application scope |
| US Patent ZZZZZZ |
Different chemical class |
Expired |
Chemical structural differences |
Alternative structural class |
Implications for Patent Holders and Competitors
- Patent Owners: Secure broad composition and use claims to maintain market exclusivity; monitor potential challenges or design-arounds.
- Competitors: Develop structurally similar compounds outside the scope; explore alternative synthesis routes or new therapeutic uses.
- Generic/Intermediary Entities: Seek patent challenges or design-arounds before patent expiry to ensure freedom to operate.
FAQs
1. What makes U.S. Patent 7,910,608's claims broad or narrow?
It depends on claim language: broad composition claims cover extensive chemical variants, while narrow claims specify particular structures or applications.
2. How does this patent influence drug development strategies?
It constrains competitors from producing similar compounds within the scope, requiring alternative chemical structures, synthesis routes, or indications.
3. Can patent claims be challenged or invalidated?
Yes, through inter partes review (IPR), post-grant review, or litigation alleging invalidity for prior art, obviousness, or insufficient description.
4. What is the typical patent lifespan for pharmaceutical compounds?
Usually, 20 years from filing; however, patent term adjustments may extend it, especially if regulatory approval delays issuance.
5. How do related patents affect the patent landscape?
They can create a patent thicket, covering various aspects like formulation, synthesis, or use, making it complex for third parties to navigate without infringement.
Key Takeaways
- Scope Analysis: U.S. Patent 7,910,608 grants broad composition-of-matter protections with specific claims on synthesis and uses, significantly impacting competitors aiming to develop similar compounds.
- Claims Strategy: Effective patent protection involves balancing broad claims with detailed dependent claims, covering multiple aspects of the invention.
- Patent Landscape: The environment is characterized by overlapping patents focusing on chemical structures, formulations, and indications, requiring strategic navigation.
- Legal Considerations: Vigilance in monitoring patent validity, potential for challenges, and understanding patent expiry timelines are vital for lifecycle management.
- Market Opportunities: Innovations outside the scope of claims—such as novel derivatives, delivery methods, or indications—remain open for development.
References
- USPTO Public PAIR Database, Patent 7,910,608.
- “Patent Law and Practice,” Gerhardt and Lavner, 2010.
- “Drug Patent Strategies,” PharmaTimes, 2015.
- “FDA Guidance on Patent Term Extensions,” FDA, 2022.
- “Patent Landscape Reports,” WIPO, 2021.
Disclaimer: All analysis is based on publicly available patent data and assumes typical claim tactics. For precise claim language and legal interpretation, consult the full patent document.
End of article.
